The Lectin Pathway of Complement Activation Is a Critical Component of the Innate Immune Response to Pneumococcal Infection by Ali, Youssif M. et al.
 
The Lectin Pathway of Complement Activation Is a Critical




(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Ali, Youssif M., Nicholas J. Lynch, Kashif S. Haleem, Teizo
Fujita, Yuichi Endo, Soren Hansen, Uffe Holmskov, Kazue
Takahashi, Gregory L. Stahl, Thomas Dudler, Umakhanth V.
Girija, Russell Wallis, Aras Kadioglu, Cordula M. Stover, Peter
W. Andrew, and Wilhelm J. Schwaeble. 2012. The lectin pathway
of complement activation is a critical component of the innate
immune response to pneumococcal infection. PLoS Pathogens
8(7): e1002793.
Published Version doi:10.1371/journal.ppat.1002793
Accessed February 19, 2015 10:47:54 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10454585
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAThe Lectin Pathway of Complement Activation Is a
Critical Component of the Innate Immune Response to
Pneumococcal Infection
Youssif M. Ali
1,2, Nicholas J. Lynch







5, Gregory L. Stahl
5, Thomas Dudler




1¤, Cordula M. Stover
1, Peter W. Andrew
1, Wilhelm J. Schwaeble
1*
1Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom, 2Faculty of Pharmacy, University of Mansoura, Mansoura,
Egypt, 3Department of Immunology, Fukushima Medical University, Fukushima, Japan, 4Institute of Molecular Medicine, University of Southern Denmark, Odense,
Denmark, 5Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Medical School, Boston, Massachusetts, United States of America, 6Omeros
Corporation, Seattle, Washington, United States of America
Abstract
The complement system plays a key role in host defense against pneumococcal infection. Three different pathways, the
classical, alternative and lectin pathways, mediate complement activation. While there is limited information available on
the roles of the classical and the alternative activation pathways of complement in fighting streptococcal infection, little is
known about the role of the lectin pathway, mainly due to the lack of appropriate experimental models of lectin pathway
deficiency. We have recently established a mouse strain deficient of the lectin pathway effector enzyme mannan-binding
lectin associated serine protease-2 (MASP-2) and shown that this mouse strain is unable to form the lectin pathway specific
C3 and C5 convertases. Here we report that MASP-2 deficient mice (which can still activate complement via the classical
pathway and the alternative pathway) are highly susceptible to pneumococcal infection and fail to opsonize Streptococcus
pneumoniae in the none-immune host. This defect in complement opsonisation severely compromises pathogen clearance
in the lectin pathway deficient host. Using sera from mice and humans with defined complement deficiencies, we
demonstrate that mouse ficolin A, human L-ficolin, and collectin 11 in both species, but not mannan-binding lectin (MBL),
are the pattern recognition molecules that drive lectin pathway activation on the surface of S. pneumoniae. We further show
that pneumococcal opsonisation via the lectin pathway can proceed in the absence of C4. This study corroborates the
essential function of MASP-2 in the lectin pathway and highlights the importance of MBL-independent lectin pathway
activation in the host defense against pneumococci.
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Introduction
Streptococcus pneumoniae infection is a major cause of pneumonia,
otitis media, septicemia and meningitis [1,2]. Complement–driven
opsonophagocytosis is a prominent feature of the host response to
pneumococcal infections, [3].
Complement provides protection against invading microorgan-
isms through both antibody-dependent and -independent mech-
anisms. It mediates many cellular and humoral interactions within
the immune response, including chemotaxis, phagocytosis, cell
adhesion, and B-cell differentiation. Three different pathways
initiate the complement cascade, which are known as the classical,
alternative and lectin pathways.
In the classical pathway, the recognition subcomponent C1q
binds to a variety of targets - most prominently immune complexes -
to initiate the step-wise activation of associated serine proteases, C1r
and C1s. Activated C1s cleaves C4 into C4a and C4b and then
cleaves C4b-bound C2to generate the C3convertase,C4b2a, which
converts the abundant plasma protein C3 into C3a and C3b; C3b is
the major opsonin of the complement system. Accumulation of C3b
in close proximity to the C4b2a complex leads to the formation of
the C5 convertase, C4b2a(C3b)n, which initiates the terminal
pathway of complement activation.
In the alternative pathway, spontaneous low-level hydrolysis of
C3 leads to deposition of C3b on cell surfaces, triggering
complement activation on foreign cells. Host cells are protected
by surface regulatory proteins that suppress complement activation.
Like the alternative pathway, the lectin pathway may be
activated in the absence of immune complexes. Activation is
initiated by the binding of a multimolecular lectin pathway
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(PAMPs), mainly carbohydrate structures present on microorgan-
isms or aberrant glycocalyx patterns on apoptotic, necrotic,
malignant or oxygen-deprived cells [4,5]. Rodents have at least
four circulating lectin pathway recognition molecules, with
differing, but overlapping, carbohydrate specificities; two man-
nan-binding lectins (MBL-A and MBL-C), collectin-11 (CL-11)
and ficolin A (Fcna) [6]. A second murine ficolin, Fcnb, associated
with monocyte and macrophage cell surfaces does not activate
complement in mice, but may act as a lectin pathway recognition
molecule in rats [7]. Humans have a single MBL (the product of
MBL2; MBL1 is a pseudogene), CL-11 (collectin kidney 1, CL-K1)
and three ficolins, FCN1 (M-ficolin), FCN2 (L-ficolin) and FCN3
(H-ficolin) [5,8,9].
These recognition molecules form complexes with three serine
proteases, MASP-1, -2 and -3 (MBL-associated serine proteases 1,
2 and 3). The recognition molecules also interact with MAp19 and
MAp44 (alias MBL/ficolin-associated protein 1), which are non-
enzymatic, truncated alternative splice products of the MASP2 and
MASP1/3 genes, respectively. Both truncated gene products lack
the serine protease domain and may regulate lectin pathway
activation by competing for the binding of MASPs to the
carbohydrate recognition molecules [4,10–15].
Of the three MASPs, only MASP-2 is required and essential to
form the lectin pathway C3 and C5 convertases (C4b2a and
C4b2a(C3b)n) [6,10,16,17].
Like C1s, activated MASP-2 cleaves C4 and C4b-bound C2,
generating C4b2a, the classical and lectin pathway C3 convertase.
Neither MASP-1 nor MASP-3 can cleave C4 and therefore cannot
compensate for the absence of MASP-2. Thus, formation of the
lectin pathway C3 and C5 convertase complexes is impossible in
absence of MASP-2 [6]. MASP-1 appears to facilitate lectin
pathway activation by either direct cleavage of complex-bound
MASP-2 or cleavage of C4b-bound C2, but MASP-1 cannot drive
lectin pathway activation in the absence of MASP-2, as MASP-2 is
required to initiate the formation of the lectin pathway convertases
by the cleavage of C4 [6,18,19]. Interestingly, recent work
demonstrated that MASP-1 (and possibly MASP-3) play a key
role in the maturation and initiation of the alternative activation
pathway [20,21].
Infection studies using mice with targeted deficiencies in one or
more complement components have provided evidence for the
roles of the classical and alternative pathways in protection against
S. pneumoniae. C1q deficient mice were found to be more
susceptible to infection with S. pneumoniae than WT mice,
indicating that the classical pathway has a protective role. The
alternative pathway was also found to have a protective role
against S. pneumoniae, but to a lesser extent than the classical
pathway. Mice deficient in factor B had a significantly higher level
of bacteria in lungs and in blood in comparison to their WT
controls [22].
The contribution of the lectin activation pathway towards the
defense against S. pneumoniae infection had not been assessed so far,
mainly due to the lack of appropriate mouse models of total lectin
pathway deficiency.
Using MASP-2 deficient mice, completely devoid of the ability
to form lectin pathway C3 and C5 convertases, this report
demonstrates that lectin pathway activation provides a critical
degree of protection against S. pneumoniae. We identified mouse
ficolin A and CL-11, but not MBL-A or MBL-C, to be the critical
pattern recognition molecules that initiate complementactivation
via the lectin pathway on the surface of this pathogen.
Results
The lectin pathway drives complement deposition on S.
pneumoniae
Complement deficient sera were used to determine which
components contribute to C3b opsonisation of S. pneumoniae. C3b
deposition was assayed by ELISA using formalin-fixed bacteria
and by FACS analysis using live bacteria. MASP-2 deficiency
leads to a total loss of C3b deposition (fig. 1a–e). Using a simple
end-point ELISA, C3b deposition appears to be unaffected by
factor B deficiency (fig. 1b). However, the conversion of C3 is
slower in factor B deficient serum (t1/2<28 min) than in WT
serum (t1/2<8 min), indicating that the alternative pathway
amplification loop contributes to the C3 turnover (fig. 1c). Serum
from MBL-null mice (deficient in both MBL-A and MBL-C)
opsonised the bacteria as efficiently as WT serum, whereas ficolin
A deficiency resulted in impaired C3b deposition. Ficolin B was
not detectable in sera of WT and ficolin A deficient C57BL/6
mice (data not shown). Serum deficient in MBL-A, MBL-C and
ficolin A produced similar results to those seen using ficolin A
deficient serum, suggesting that the remaining lectin pathway
recognition component CL-11 may drive residual lectin pathway
activation on S. pneumoniae (fig. 1b). In addition to the recent
publication by Hansen et al. (2010) [9] which demonstrated
MASP-1 binding to CL-11, we have shown that recombinant
human CL-11 binds recombinant MASP-2 to form a lectin
pathway activation complex under physiological conditions (fig.
S1).
Using C4 deficient mouse serum, the absolute amount of C3b
deposited on S. pneumoniae was approximately half that observed
using WT serum (fig. 1b, c, e & f) and the rate of conversion was
lower (T1/2<30 min in C4 deficient serum; 8 min in WT serum;
fig. 1c). C4 is an integral part of the classical and lectin pathway
C3 convertase, C4b2a, suggesting that the residual C3b deposition
seen in C4 deficient serum is a result of either alternative pathway
activation [23], [24] or the recently reported lectin pathway-
Author Summary
Streptococcus pneumoniae is a major human pathogen that
causes pneumonia, septicemia and meningitis. The host
defense against pneumococci is largely dependent on
complement, a system of blood proteins which, when
activated, attach to bacteria, targeting them for clearance
by phagocytes. There are three routes of complement
activation: The classical, lectin and alternative pathways.
Limited information is available on the roles of the classical
and alternative pathways in fighting pneumococci; the role
of the lectin pathway has escaped the attention of
previous research. This work demonstrates that the lectin
pathway is critical in fighting pneumococcal infection. Of
the five different lectin pathway recognition molecules in
human serum, only L-ficolin and collectin 11 activate
complement on pneumococci. Human mannose-binding
lectin (MBL), the best-known lectin pathway pattern
recognition molecule, has no role whatsoever in fighting
pneumococci. Similarly, in mouse serum, only ficolin A and
collectin 11 drive complement activation on S. pneumo-
niae. Hence, MBL deficient mice are not compromised in
pneumococcal infection, while ficolin A deficient mice and
mice deficient of the key lectin pathway enzyme MBL-
associated serine protease-2 (MASP-2) are exquisitely
susceptible to infection. This work explains why MBL
deficiency, the most frequent hereditary immune deficien-
cy, does not predispose to pneumococcal disease.
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carried out at low serum concentrations (1.25%, fig. 1b; 2.5%,
fig. 1c and; 5%, fig. 1e & f) where the alternative activation
pathway is dysfunctional, and (ii) the activation of C3 on the
surface of S. pneumoniae is absent in MASP-2 deficient mice (see
fig. 1), we conclude that the C3 deposition on S. pneumoniae in C4
deficient serum is mediated by the MASP-2 dependent C4-bypass
activation route. Likewise, inhibition of MASP-2 activity with the
anti-MASP-2 mAb AbD04211 abolished C3b deposition on S.
pneumoniae incubated with C4 deficient serum, supporting the
hypothesis that the MASP-2 dependent C4-bypass plays a
significant role in the opsonisation of S. pneumoniae (fig. 1f).
Similar results were obtained using human serum from a donor
with a complete deficiency of both C4 genes, C4A and C4B:C 4
deficiency halved C3b deposition, although the EC50 value was
unaffected (<0.05% for all sera assayed; fig. 1g). Human MBL
deficiency had no impact on the deposition of C3b on the surface
of S. pneumoniae (see fig. 1g). In contrast, analysis of 47 samples of
normal human serum (NHS) revealed a significant correlation
between serum L-ficolin concentration and the level of C3b
deposition S. pneumoniae (fig. 2f; p,0.0001; Fisher transformation
of Pearson’s correlation coefficient). The test group included 8
MBL deficient sera (YO/YO or YO/XA genotypes, see [25]),
none of which showed abnormally low C3b deposition, providing
further evidence that that human MBL does not contribute to
complement activation on S. pneumoniae.
Haemolytically active C4b is undetectable on the surface
of S. pneumoniae after serum exposure
Antibodies directed against the larger C4 activation fragments,
C4b and C4c, failed to detect any C4 deposition on the surface of
S. pneumoniae exposed to normal human serum (fig. 2a & c).
However, when using an antibody directed against C4dg, the
haemolytically inactive final degradation product of C4, an
abundant deposition of covalently bound C4dg was detected
(fig. 2b & d), supporting the hypothesis that S. pneumoniae sequester
host complement control proteins to accelerate the degradation
and inactivation of C4b [26,27].
Binding of lectin pathway recognition molecules to S.
pneumoniae
A series of solid-phase binding experiments were performed to
identify lectin pathway recognition molecules that bind to S.
pneumoniae. Microtitre plates coated with S. pneumoniae D39 and
control substrates were used to capture lectin pathway recognition
molecules from WT mouse serum and NHS (fig. 3). As anticipated
from the C3b deposition assays (fig. 1b & g) and previous reports
[28], MBL does not recognize the bacteria, whereas murine Fcna
(fig. 3b) and CL-11 (fig. 3c), and human L-ficolin and CL-11 (alias
CL-K1) (fig. 3f) do. Direct binding to the bacterial surface was
confirmed using recombinant human CL-11 and mouse ficolin A
(data not shown).
Figure 1. MASP-2 is essential for C3 deposition on S pneumoniae. Serial dilutions of sera were incubated in microtiter plates coated with S.
pneumoniae D39 or N-acetylated BSA (as a control), and C3 deposition determined by ELISA. A. Shows the raw data from one experiment with WT
and MASP-2 deficient murine serum (means 6SEM). In B, the experiment was extended to include murine sera deficient in other complement
components. Results are duplicates (6SD) and are normalised to the C3 deposition observed in the WT control. C. Time course of C3 activation on S.
pneumoniae. 1:40 diluted murine sera were incubated in microtiter plates coated with S. pneumoniae for the times indicated then C3 deposition
assayed. Results are means of duplicates and are representative of three independent experiments. D. FACS analysis of C3 deposition on S.
pneumoniae opsonised with MASP-2 2/2 serum (black line), WT serum (red) and C4 2/2 serum (green). The blue trace shows non-opsonised
bacteria. E. Results from 3 independent FACS analyses of C3 deposition (mean fluorescent intensity 6SEM). F. Inhibition of MASP-2 activity with mAb
AbD04211 abolished C3b deposition on S. pneumoniae opsonised with C4 deficient serum. (means of triplicates 6SEM; p value from Student’s t-test).
G. In human serum, MBL deficiency had no effect on C3 deposition, while C4 deficiency had no significant effect on the EC50, but reduces absolute
C3b deposition by about 50% (means 6SEM; n=3 for NHS and MBL 2/2 serum, 1 for C4 deficient serum). H. Correlation between L-ficolin serum
concentration and C3b deposition on S. pneumoniae immobilised on microtiter plates for 47 samples of NHS (solid line shows Fisher transformation
of Pearson’s correlation coefficient; dashed lines, 95% CI thereof).
doi:10.1371/journal.ppat.1002793.g001
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serotypes (18, 6B and 3) were tested for binding of human and
murine recognition molecules. With human serum the results were
remarkably consistent: Of the 5 different lectin pathway specific
carbohydrate recognition subcomponents, only L-ficolin and
CL11 (alias CL-K1) bound to the bacteria (table S1). Most of
the strains showed little or no binding to murine MBL-C and none
bound MBL-A. All of the strains tested bound murine CL-11 with
similar affinities, and all strains tested bound Ficolin A. MBL-C
and Ficolin A binding differed amongst strains of the same
serotype, indicating that capsular polysaccharide is unlikely to be
the main determinant of recognition by lectin pathway recognition
subcomponents.
MASP-2 is essential for opsonophagocytosis of S.
pneumoniae
The inability of MASP-2 deficient mouse serum to opsonise S.
pneumoniae with C3b led to defective phagocytosis in vitro (fig. 4). S.
pneumoniae D39 were opsonised with WT or MASP-2 deficient
serum and mixed with freshly isolated human peripheral blood
polymorphonuclear leukocytes (PMN). Bacteria opsonised with
WT serum were internalised (fig. 4a & c), whereas bacteria
opsonised with MASP-2 deficient serum were excluded from the
PMN, indicative of defective uptake and phagocytosis (fig. 4b).
Samples taken from the mixture over a period of 2 hr were plated
on blood agar and viable S. pneumoniae counted (fig. 4d).
Pneumococci mixed with WT serum are efficiently killed by
PMN, while those opsonised with MASP-2 deficient serum survive
as well as non-opsonised controls. In addition, 20% MASP-2
sufficient (WT) serum from non-immunized mice has no
bacteriolytic activity on S. pneumoniae. This observation was
confirmed using 50% WT mouse and human serum (data not
shown).
Lectin pathway deficient mice are susceptible to S.
pneumoniae infection
We used MASP-2 and Fcna deficient mice to determine to what
extent the lectin pathway contributes to host defense against S.
pneumoniae in vivo. In contrast to MBL-null [29] and Fcna deficient
mice [30] (both of which having lectin pathway activation
complexes formed with the remaining recognition molecules in
their blood), MASP-2 deficient animals are unable to form the
lectin pathway C3 and C5 convertases [6].
Ten-week old C57BL/6
Masp22/2 mice and WT littermates were
infected with S. pneumoniae D39 by intranasal inoculation and the
course of the infection monitored for one week (fig. 5). 75% of the
WT mice survived the infection, compared with only 20% of the
MASP-2 deficient mice (p=0.0006).
During the first 12 hours after infection, the WT mice showed
signs of an initial clinical response (hunching), while the MASP-
22/2 mice appeared unaffected. In both groups, the first animals
reached the endpoint (severe lethargy) after 48 hours, and survival
dropped further until 72 hrs after infection. All those animals alive
after 72 hr survived (see fig. 5a). In another series of experiments,
animals were sacrificed 12, 24 and 48 hr post infection to
determine counts of viable S. pneumoniae in lung homogenate and
blood. In MASP-2 deficient mice, CFUs in the lung (fig. 5c) and
blood (fig. 5e) were significantly higher than in WT mice and rose
progressively during the first 48 hr, at which point the experiment
was stopped due to the high mortality in the MASP-2 deficient
group. In WT mice that survived the first 72 hr, bacteria were
progressively cleared from the both the lungs and blood. Similar
results were obtained with C57BL/6
Fcna2/2 mice; 70% of the WT
littermates survived, whereas 80% of the ficolin A deficient mice
succumbed to the infection (fig. 5b). Lung infection and
bacteraemia are shown in fig. 5d and f.
In contrast, intranasal infection of C57BL/6
MBL-null (MBL-A
and MBL-C double deficient) mice resulted in neither signifi-
cantly increased mortality nor compromised bacterial clearance
mice compared to sex and age matched C57BL/6 WT controls
(fig. S2).
Quantitative RT-PCR analysis of cytokine and chemokine
expression in lungs from infected animals showed that the onset of
the inflammatory response was broadly similar in WT, ficolin A
and MASP-2 deficient mice. After 12 hr, however, the pro-
inflammatory TNFa response increased more rapidly in the lectin
pathway deficient mice, and levels were significantly greater at
Figure 2. Deposition of C4 breakdown products on S. pneumoniae. ELSIA plates were coated with S. pneumoniae D39, E. coli or mannan (as
positive controls) and incubated with NHS for 1 h at 37uC. Bound C4 was detected using an antibody against C4c (which also detects C4b) (A)o ra n
antibody against C4dg, the last breakdown product of C4 that remains covalently attached to the activating surface (B). C and D: Detection of C4c (C)
and C4dg (D) on live S. pneumoniae D39 opsonised with NHS. Green trace shows anti-C4 antibodies; the purple shading, an isotype control Ab.
doi:10.1371/journal.ppat.1002793.g002
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the IL6 response was also elevated. The INFc response was
significantly greater in the ficolin A deficient mice. In the ficolin A
and MASP-2 deficient mice, MIP-2 (CLCX2) expression persists
at 48 hr, indicating on-going macrophage activation at a time
when the response is abating in the WT mice (fig. S3).
MASP-2 deficiency can be simulated in WT mice using a mAb
that specifically inhibits MASP-2. A single i.p. dose of 0.6–1.0 mg/
Figure 3. Binding of lectin pathway recognition molecules to S. pneumoniae. Microtiter plates coated with formalin-fixed S. pneumoniae or
control substrates were used to capture lectin pathway recognition complexes from WT mouse serum or NHS. Murine MBL-A and MBL-C (A), murine
ficolin A (B), murine CL-11 (C) human MBL (D), FCN1 & 3 (E) and FCN2 and CL-K1 (F) were assayed by ELISA, as described in materials and methods.
Only ficolin A, CL-11 and FCN2 (L-ficolin) bound to the bacteria. Results are means of duplicates and are representative of three independent
experiments.
doi:10.1371/journal.ppat.1002793.g003
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for up to 7 days [6]. WT mice treated with this mAb prior to
infection with S. pneumoniae had significantly greater mortality and
higher bacteraemia than untreated controls (fig. 6). Antibiotic
treatment (Ceftriaxone, 20 mg per kg body weight i.p. 12 h before
infection and every 12 h thereafter) resulted in complete
protection against mortality in both Ab-treated and non-treated
groups. These results suggest that increased susceptibility to S.
pneumoniae in MASP-2 deficient mice is a direct result of the loss of
MASP-2 driven lectin pathway activity, rather than an indirect
result of MASP-2 deficiency on the development of the animal’s
immune response.
Discussion
Complement-dependent opsonophagocytosis is a key feature of
the host defense against S. pneumoniae. Thirty years ago, using a
guinea pig model of pneumococcal bacteraemia, it was shown that
the clearance of IgG and IgM opsonized pneumococci from the
circulation is entirely dependent upon complement; animals
deficient of C4, or depleted of complement using cobra venom
factor (CVF), fail to clear the bacteria [31]. More recently, Brown
and co-workers [22] used mice with engineered genetic deficien-
cies to demonstrate the importance of C1q, C4 and C3 in the
defense against S. pneumoniae. Based on the observation that C1q
deficient mice are as susceptible to infection as C4 deficient mice,
the authors concluded that activation of the classical pathway is
the predominant mechanism for complement-mediated opsoniza-
tion and phagocytosis of S. pneumoniae and that the lectin pathway
(which according to the present text book view requires C4 to
work) plays a negligible role [22].
Here we analyzed experimental S. pneumoniae infection in the
first available model of lectin pathway deficiency and reached the
conclusion that the lectin pathway promotes innate resistance
against pneumococcal infection in the non-immunized host. The
results presented here show that MASP-2 deficient mice (which
can still activate complement via the classical and alternative
pathways [6]) are severely compromised in their ability to survive
S. pneumoniae infection (fig. 5). Survival times and mortality rates
were similar to those reported for C1q and C4 deficient mice,
using the same strains of bacteria and mice, and the same dose and
route of infection [22].
Neither the classical, nor the alternative activation pathway
could compensate for the loss of lectin pathway mediated C3
opsonization of S. pneumoniae. In contrast, the absence of C1q had
no effect on C3 opsonization of these bacteria in vitro (fig. 1)
implying that C1q may contribute to bacterial clearance in a
process independent of direct C3b or iC3b deposition on the
bacterial surface.
Deficiency of factor B, a component of the alternative pathway
C3 convertase led to a significantly slower C3 turnover (fig. 1C),
This is probably due to the loss of the alternative pathway
amplification loop, a positive feedback mechanism that amplifies
C3 activation via of all three pathways, which may account for the
reported susceptibility of factor B deficient mice to S. pneumoniae
infection (Brown et al., 2002).
As previously reported by others [26,32], we were unable to
detect any C4b or C4c on the surface of S. pneumoniae opsonized
with normal human serum (fig. 2). However, the bacterial surface
was abundantly decorated with C4dg, the final product of C4
decay. This finding strongly supports the hypothesis that S.
pneumoniae avoids the accumulation of active C4b by sequestrating
complement regulatory proteins from host serum to accelerate the
breakdown of C4b, thus preventing the formation of the C3
convertase C4b2a on the pathogen, rather than by preventing C4
binding. Recent work suggests that the pneumococcal virulence
factors PspA and PspC are responsible for recruiting factor H and
C4-binding protein from host plasma, both of which accelerate the
factor I-mediated breakdown of C4b to C4dg [26,27].
C3 deposition on pneumococci was impaired, but not
completely blocked, by C4 deficiency in both mice (fig. 1b–f)
and humans (fig. 1g). In the mouse, C4 deficiency led to a
significantly slower C3 turnover and in both species the absolute
amount of C3 deposited on the bacteria was approximately half of
that observed using WT serum. The residual C3 deposition in C4
deficient murine serum could be inhibited using a monoclonal
antibody directed against MASP-2 (fig. 1f), indicating that the
MASP-2-dependent C4-bypass is active on S. pneumoniae [6].
Nevertheless, C4 deficient mice have an increased susceptibility to
S. pneumoniae infection ([22]; our unpublished data), indicating that
the MASP-2-dependent C4-bypass only partially compensates for
C4-dependent lectin pathway activation in this setting. The C4-
bypass activation of the lectin pathway was shown to play a
significant physiological role in ischemia-reperfusion injury;
MASP-2 deficient mice are protected from reperfusion injury
following myocardial ischemia, whereas C4 deficient mice are not
[6,33].
Figure 4. MASP-2 deficiency impairs phagocytosis of S.
pneumoniae by polymorphonuclear leukocytes. S. pneumoniae
were pre-incubated with murine serum (20% v/v), mixed with freshly
isolated human PMN and incubated for 2 hr before being immobilised
on microscope slides and stained with eosin Y and azur II (REASTAIN), as
described in materials and methods. Bacteria opsonised with WT serum
(A) are internalized by PMNs, whereas bacteria opsonised with MASP-2
2/2 serum (B) are excluded (arrows). C. Electron micrograph showing
pneumococci opsonised with WT serum inside a PMN. D. Samples were
removed from the S. pneumoniae/PMN mix at the times indicated and
viable bacteria determined. WT serum (crosses) facilitated killing by
PMN, whereas MASP-2 2/2 serum (open squares) is severely
compromised in its ability to opsonise S. pneumoniae. Controls were
run in parallel containing non-opsonised bacteria (triangles) and
bacteria opsonised with WT serum, but without PMN (circles). Results
are means (6SEM) of triplicates.
doi:10.1371/journal.ppat.1002793.g004
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bacterial surface seriously compromises the ability of the classical
pathway to form a C3 convertase and thus opsonize S. pneumoniae
with C3b, while the lectin pathway is still able to opsonize
pneumococci with C3b via the C4-bypass, which provides a
physiologically relevant degree of compensation for the impaired
C4-dependent activation of C3 [6]. The loss of lectin pathway
activity caused by MASP-2 deficiency or MASP-2 inhibition
would remove a critical degree of C3 opsonization of S. pneumoniae
in naive mice and hence explain the phenotype of compromised
pneumococcal clearance in MASP-2 deficient or MASP-2
depleted mice. The rapid conversion of C4b to C4dg on the
pathogen surface appears to be a feature of S. pneumoniae. This
would explain why the absence of lectin pathway activity renders
the host more susceptible to infections with this particular
pathogen, whilst no increased predisposition to, or severity of,
infection with other major pathogens, e.g. Pseudomonas aeruginosa
and Neisseria meningitidis were observed in MASP-2 deficient mice
([34]; our unpublished data).
In murine serum, it is predominantly ficolin A and CL-11 that
bind to S. pneumoniae (fig. 3 and table S1). The binding of both
lectin pathway recognition molecules to the bacterial surface was
confirmed using recombinant human CL-11 and recombinant
murine ficolin A. Murine MBL-A does not bind to any of the S.
pneumoniae strains studied here (covering 4 serotypes), and MBL-C
bound weakly or not at all (table S1). It was therefore not
surprising that the presence or absence of both MBL-A and MBL-
C in C57BL/6 mice had no impact on overall survival in our
model of S. pneumoniae D39 infection. In contrast, following
pneumococcal infection, C57BL/6
Fcna2/2 mice were severely
compromised with a significantly higher degree of mortality and
higher bacterial loads in blood and lung tissue than WT controls.
Figure 5. Lectin pathway deficiency significantly increases the severity of S. pneumoniae infection. Lectin pathway deficient mice (open
squares) and WT littermates (crosses) were infected intranasally with 1610
6 cfu S. pneumoniae D39. C57/BL6
Masp22/2 (A) and C57/BL6
Fcna2/2 (B)
mice are impaired in their survival of S. pneumoniae infection (Mantel-cox log-rank test). C–F. Viable S. pneumoniae counted in lung homogenates
and peripheral blood at the indicated time points after infection. Results in C–E are means (6SEM) of five animals sacrificed at each time point.
*p,0.05; **p,0.01 (ANOVA).
doi:10.1371/journal.ppat.1002793.g005
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ficolin A (but not MBL-A or MBL-C) is a key recognition
component of the lectin activation pathway in the innate host
defense against pneumococcal infection. Interestingly, serum from
mice deficient in all lectin pathway recognition components except
CL-11 still deposits C3b on the surface of S. pneumoniae (fig. 1b).
Since mouse CL-11 binds strongly to the surface of S. pneumoniae
(see fig. 3c) and since we show that CL-11 also forms complexes
with the lectin pathway effector enzyme MASP-2 (fig. S1), we
conclude that CL-11 acts synergistically with ficolin A as an
initiator of lectin pathway activation following binding of specific
PAMPs on the pneumococcal surface.
The situation is similar in humans; only L-ficolin and CL-11
recognize S. pneumoniae (fig. 3e & f). As previously reported by
others [28], we found no binding of MBL to any of the
pneumococcal strains (table S1), and there was no indication that
MBL deficiency leads to defective C3b deposition on the bacteria
(fig. 1g&h). As MBL deficiency is the most common hereditary
complement deficiency in humans, affecting as many as 1 in 10 of
the population [35], there has been much interest in the possibility
of an association between MBL deficiency and infectious disease.
In the case of S. pneumoniae, the results of association studies have
been largely negative or inconclusive, with two of the largest
studies finding no association between the risk of community-
acquired pneumonia and MBL deficiency [36,37]. Genetic
variations of the L-ficolin gene are more subtle, with no complete
functional deficiency in adults reported to date. Furthermore,
there is no apparent association between polymorphisms in FCN2
that lead to low levels of L-ficolin and pneumococcal disease [38],
indicating that even low levels of L-ficolin and/or the presence of
CL-11 are sufficient to mount a robust immune response against S.
pneumoniae.
We have previously shown that antibodies to MASP-2 can block
lectin pathway driven inflammation and limit tissue loss in
ischaemic pathologies [6], suggesting therapeutic utility for anti
MASP-2 antibody therapy. Our experiments show that such
treatment may increase susceptibility to S. pneumoniae infection in
naive mice. Pneumococcal vaccination history or immune status
may need to be considered prior to initiating anti MASP-2
treatment in patients. Alternatively, since the increased suscepti-
bility was completely reversed by concurrent treatment with
ceftriaxone, MASP-2 antagonists should be safe to use with
appropriate prophylactic antibiotic treatment.
The results of this study call for a revision of the previously
published conclusion by Brown et al. (2002) [22] that the lectin
pathway of complement activation is not a major player in the host
response to S. pneumoniae infection. This conclusion led the same
research team to exclude any involvement of the lectin pathway in
the clearance of pneumococci in subsequent publications. When
studying the impact of human C2 deficiency on C3b opsonization
and phagocytosis of S. pneumoniae [39], no consideration was given
to the fact that C2 deficient individuals are not only deficient of the
classical activation pathway, but also of C3 and C5 convertases
formed by the lectin pathway. The results presented here,
however, strongly suggest that in none-immune sera, it is the loss
of lectin pathway functional activity that accounts for the loss of
C3b/iC3b opsonization of pneumococci.
Finally, we describe clear evidence of lectin pathway activation in
a physiological context in the absence of a discernable contribution
by MBL. Thus, the prevailing view that MBL is the predominant
initiator of lectin pathway activation may need to be revisited.
Materials and Methods
Ethics statement
All animal experiments were authorized by the UK Home
Office (Animals Scientific Procedures Act 1986; Home Office
project licence 80/2111) and approved the University of Leicester
animal welfare committee. Every effort was made to minimize
suffering and mice were humanely culled if they became lethargic
during infection experiments.
Materials
Unless otherwise stated, all reagents were obtained from Sigma-
Aldrich. PSA, a polysaccharide produced by Aerococcus viridans that
binds FCN3 was prepared as previously described [40].
AbD04211, a recombinant mAb that potently inhibits mouse
MASP-2, has been described previously [6].
Bacteria
S. pneumoniae serotype 2 strain D39 was obtained from the
National Collection of Type Cultures, London, United Kingdom
Figure 6. Inhibition of MASP-2 increases the severity of S. pneumoniae infection. WT C57/BL6 mice were dosed i.p. with 1.0 mg/kg body
weight of anti-MASP-2 mAb AbD04211 (open triangles) or an isotype control mAb (crosses) 12 h before being infected with 1610
6 cfu S. pneumoniae
D39. MASP-2 inhibition significantly worsened survival (A) and there was a corresponding increase in viable S. pneumoniae counted in peripheral
blood after infection (B). Treatment with 20 mg/kg body weight ceftriaxone 12 hr before infection and every 12 hr thereafter afforded complete
protection from S. pneumoniae in animals injected with AbD04211 (filled triangles in A). Results in B are means (6SEM) of twelve animals from which
blood was taken at each time point. *p,0.05 (ANOVA).
doi:10.1371/journal.ppat.1002793.g006
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staining, catalase testing, alpha-hemolysis on blood agar plates,
and determination of optochin sensitivity. Serotypes were
confirmed by the Quellung reaction. To obtain pneumococci
grown in vivo, bacteria were cultured and passaged through mice as
described previously [41] and subsequently recovered and stored
at 270uC. When required, suspensions were thawed at room
temperature and bacteria were harvested by centrifugation before
re-suspension in sterile PBS. Nine other clinical isolates of S.
pneumoniae were kindly provided by Prof. Herminia de Lancastre,
Instı ´tuto de Tecnologia Quı ´mica e Biolo ´gica, Oeiras, Portugal
[42].
Mice and murine sera
Mice deficient in MASP-2 and C4 have been described
elsewhere [6,43]. Ficolin A deficient mice were generated by
targeting Fcna using a conventional replacement vector, as
described elsewhere [44]. MBL-null mice were purchased from
MMRRC, Bar Harbor, Maine and crossed with Fcna2/2 mice to
produce a strain deficient in all three components. Complement
deficient mouse strains were backcrossed with C57/BL6 mice for
at least ten generations before use. Blood was collected from these
animals and from WT C57/BL6 mice by cardiac puncture, serum
prepared, aliquoted and stored at 280uC. C1q deficient and factor
B deficient murine plasma was kindly provided by Dr. Marina
Botto, Imperial College London.
Human sera
Human blood was obtained from healthy adult donors who had
given written, informed consent, as required by the local ethics
committee. L-ficolin concentration was determined as previously
described [45]. Genomic DNA was prepared using a kit (Promega)
and MBL2 A/O and X/Y genotypes were determined using
fluorescent hybridization probes in a Roche LightCycler [46].
Serum from an individual with a complete deficiency of both C4
genes, C4A and C4B, has been described previously [47].
Solid phase binding assays
Nunc Maxisorb microtiter plates were coated with 100 ml of the
following reagents: 10 mg/ml mannan (a control for MBL
binding), 10 mg/ml zymosan (a control for CL-11 binding),
10 mg/ml N-acetylated BSA (Promega; a control for ficolin A
binding), 5 mg/ml of the FCN2-specific mAb GN4, 10 mg/ml
PSA, or formalin-fixed S. pneumoniae D39 (OD550 nm=0.6) in
coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6).
Wells were blocked with 250 ml of 1% (w/v) BSA in TBS buffer
(10 mM Tris-HCl, 140 mM NaCl, pH 7.4), then washed three
times with 250 ml of TBS with 0.05% Tween 20 and 5 mM CaCl2
(wash buffer). Serial dilutions of serum in 100 ml of wash buffer
were added and the plates incubated for 90 min at room
temperature. Plates were washed as above and bound proteins
detected using monoclonal rat anti-mouse MBL-A (Hycult), rat
anti-mouse MBL-C (Hycult), rabbit anti-mouse ficolin-A, rabbit
anti-human M-ficolin, rabbit anti-human L-ficolin, mouse anti-
human H-ficolin, mouse anti-human CL-11 or rat anti-mouse CL-
11 mAbs. Secondary antibodies were alkaline phosphatase-
conjugates and bound antibody was detected using the colorimet-
ric substrate p-nitrophenylphosphate (pNPP).
Complement assays
To measure C3 and C4 activation, Nunc MaxiSorb microtiter
plates were coated with 100 ml of: 10 mg/ml mannan (Promega),
or formalin-fixed S. pneumoniae D39 (OD550 nm=0.6) in coating
buffer. After overnight incubation, wells were blocked with 0.1%
HSA in TBS then washed with wash buffer. Serum samples were
diluted in BBS (4 mM barbital, 145 mM NaCl, 2 mM CaCl2,
1 mM MgCl2, pH 7.4), added to the plates and incubated for
1.5 h at 37uC. The plates were washed again, and bound C3b or
C4b was detected using rabbit anti-human C3c (Dako) or rat anti
mouse C4 (Hycult) followed by alkaline phosphatase-conjugated
goat anti-rabbit IgG or alkaline phosphatase-conjugated rabbit
anti rat IgG followed by the colorimetric substrate pNPP.
FACS analysis
S. pneumoniae D39 were washed twice with TBS and re-
suspended in BBS to a concentration of 10
6 cfu/ml. Two hundred
ml of the bacterial suspension was mixed with 10 ml of NHS, WT
mouse or complement deficient mouse serum and incubated for
1 h at 37uC. After opsonization, the bacteria were washed twice
with wash buffer, re-suspended in wash buffer containing FITC
conjugated rabbit anti-human C3c (Dako), mouse anti-human
C4dg (Quidel) or mouse anti-human C4c (Santa Cruz) and
incubated for 1 h on ice. Where non-conjugated primary
antibodies were used, the pneumococci were washed twice and
incubated for a further hour with FITC conjugated anti-mouse
IgG (Dako). After two further washes, the bacteria were fixed using
1% w/v paraformaldehyde, and fluorescence intensity measured
by FACS (Becton Dickinson FACS Calibur).
Phagocytosis assay and bactericidal activity assay of
serum complement
Polymorphonuclear leukocytes (PMN) were isolated from fresh
human blood by discontinuous density gradient centrifugation
using Histopaque-1119 and Histopaque-1077, according to the
manufacturer’s instruction. Leukocytes were washed twice with
Hank’s balanced salt solution (HBSS) containing 1.2 mM Ca
2+
and 1.2 mM Mg
2+, pH 7.4 (Invitrogen) and re-suspended in
HBSS to a concentration of 10
7 cells/ml.
Killing of pneumococci by PMN was estimated by measuring
the decrease in viable bacteria over time. Pneumococci were
opsonized by incubation with 20% v/v WT or complement
deficient murine serum at 37uC for 30 min. 1610
6 PMNs were
mixed with 10
5 pre-opsonized or non-opsonized S. pneumoniae D39
in a final volume of 250 ml in HBSS and incubated at 37uCo na
rotary mixer. Samples were taken at 0, 30, 60, 120 and 240 min.
To determine viable bacteria, samples were serially diluted in
HBSS and plated onto blood agar plates.
For histological staining, 25 ml samples of the PMN/pneumococci
mix were attached to glass slides by centrifugation at 15006gf o r
3 min in a Cytospin 2 (Shanon). The slides were air dried for 15 min
and stained using the RESTAIN Quick Diff. Kit (REAGENA). The
slides were washed with water, air-dried and then mounted in DPX
resin and photographed by bright-field microscopy.
For Transmission Electron Microscopy (TEM), a PMN/
pneumococci mix was centrifuged for 5 min at 2506 g. Cells
were washed twice with 500 ml of 0.1M PBS (pH 7.2) and then
fixed by re-suspension into 250 ml of 2.5% glutaraldehyde in 0.1
M PBS (pH 7.2). Fixed PMNs were then examined by TEM.
To assess whether serum complement alone can reduce the
number of recoverable S. pneumoniae D39 through complement-
mediated lysis, bacteria were incubated for 240 min. in 20% and
50% WT human and mouse sera at 37uC on a rotary mixer,
samples taken at 0, 30, 60, 120 and 240 min and plated onto
blood agar to determine viable bacteria.
Infection experiments
Ten to twelve week old female MASP-2 and Fcna deficient
mice, and their WT littermates were used. Mice were lightly
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oxygen (1.5 to 2 litre/min), and 50 ml PBS containing 1610
6 cfu
of S. pneumoniae D39 was then administered into the nostrils of the
mice. The inoculum dose was confirmed by viable count after
plating on blood agar. For survival experiments, mice were
monitored for clinical signs and culled when they became severely
lethargic. This time was recorded as the survival time. To
determine bacterial tissue counts, groups of mice were deeply
anaesthetized at pre-chosen time intervals and blood was collected
by cardiac puncture. Immediately afterwards, the mice were culled
by cervical dislocation. Lungs were removed separately into 10 ml
of sterile PBS, weighed, and then homogenized in a Stomacher-
Lab blender (Seward Medical). Viable counts in lung homogenates
and blood were determined by serial dilution in sterile PBS and
plating onto agar plates supplemented with 5% (v/v) horse blood
(Oxoid) and incubated for 18 h at 37uC in anaerobic conditions.
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